# US 2005/0208060 A1 · Vaccine composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0208060 A1
- Document ID: US20050208060A1
- Status: Published application
- Kind: A1
- Application number: 10/989,154
- Filed: 2004-11-15
- Published: 2005-09-22
- Earliest claimed: 2003-11-17
- Assignees: Aventis Pasteur Limited
- Inventors: Jean Haensler
- Web page: https://patentgrep.com/patent/US20050208060A1

## CPC

- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/12: Viral antigens
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- C12N 2710/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a pharmaceutical composition comprising at least one vaccine antigen, which also comprises at least one phosphoric ester derivative of phosphatidylcholine having the structure: in which: R1 is a lower alkyl, R2 and R3 are identical or different, and can each represent linear hydrocarbon-based chains having from 13 to 21 carbon atoms.

## Claims

### Claim 1

A pharmaceutical composition comprising at least one vaccine antigen-, and at least one phosphoric ester derivative of phosphatidylcholine having the structure:
in which:
R1 is a lower alkyl,
R2 and R3 are identical or different, and can each represent linear hydrocarbon-based chains having from 13 to 21 carbon atoms.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein R1 represents the ethyl radical.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein R2 and R3 are chosen from the radicals originating from a fatty acid selected from the group consisting of myristic acid, palmitic acid, stearic acid and oleic acid.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein R2 and R3 are both identical and represent the oleic acid radical.

### Claim 5 (depends on 1)

The composition according to claim 1 further comprising an emulsion.

### Claim at position 6

6-9. (canceled)

### Claim 10

A method for immunizing a mammal, according to which at least one vaccine antigen is administered to said mammal and also administered to said mammal is a phosphoric ester derivative of phosphatidylcholine having the structure:
in which:
R1 is a lower alkyl, R2 and R3 are identical or different, and can each represent linear hydrocarbon-based chains having from 13 to 21 carbon atoms.

### Claim 11 (depends on 10)

The method according to claim 10 wherein R1 is ethyl.

### Claim 12 (depends on 10)

The method according to claim 10 wherein R2 and R3 are chosen from the radicals originating from myristic acid, palmitic acid, stearic acid or oleic acid.

### Claim 13 (depends on 10)

The method according to claim 10 wherein R2 and R3 are both identical and represent the oleic acid radical.

### Claim 14 (depends on 11)

The method according to claim 11 wherein R2 and R3 are chosen from the radicals originating from myristic acid, palmitic acid, stearic acid or oleic acid.

### Claim 15 (depends on 14)

The method according to claim 14 wherein R2 and R3 are both identical and represent the oleic acid radical.

### Claim 16 (depends on 2)

The composition according to claim 2, wherein R2 and R3 are chosen from the radicals originating from a fatty acid selected from the group consisting of myristic acid, palmitic acid, stearic acid and oleic acid.

### Claim 17 (depends on 16)

The composition according to claim 16, wherein R2 and R3 are both identical and represent the oleic acid radical.
